InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,197.26
(
0.29%
)
Post# of 4972145
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

palob

Send PM Follow Ignore
Followers 4
Posts 179
Boards Moderated 0
Alias Born 02/25/2012

palob

Re: None

Thursday, 10/29/2015 9:31:43 AM

Thursday, October 29, 2015 9:31:43 AM

Post# of 4972145
***************ELTP****************
.
ELTP_ Elite Pharmaceuticals Announces Positive Top-Line Results From A Pivotal Phase 3 Study
For Abuse-Deterrent Opioid ELI-200
.
Near term Goals :
ELI 200 submission in 2015 & approval in 2016
Continuing manufacturing facility´s expansion, equipment upgrade and staffing

- Loxapine & Dantrolene launch
- Filling two more opioid products in 2016
- ELI 200 product launch with marketing partner

Revenue growth from niche generics and first ADF product

Profitability
Base generic business profitable in 2016
R&D costs supported with ELI 200 in 2017
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up